BioCentury
ARTICLE | Company News

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

September 15, 2018 12:20 AM UTC

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication.

Teva said it expects monthly and quarterly injectable doses of Ajovy to be available within two weeks at a wholesale acquisition cost (WAC) of $575 and $1,725, respectively...